Michel W P Tsang-A-Sjoe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4780818/publications.pdf

Version: 2024-02-01

1170033 1427216 11 432 9 11 citations h-index g-index papers 11 11 11 666 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	New developments in systemic lupus erythematosus. Rheumatology, 2021, 60, vi21-vi28.	0.9	16
2	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	1.1	97
3	Treatment targets in SLE: remission and low disease activity state. Rheumatology, 2020, 59, v19-v28.	0.9	26
4	The relationship between remission and health-related quality of life in a cohort of SLE patients. Rheumatology, 2019, 58, 628-635.	0.9	36
5	A multi-parameter response prediction model for rituximab in rheumatoid arthritis. Joint Bone Spine, 2018, 85, 219-226.	0.8	22
6	Comprehensive approach to study complement C4 in systemic lupus erythematosus: Gene polymorphisms, protein levels and functional activity. Molecular Immunology, 2017, 92, 125-131.	1.0	11
7	Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology, 2017, 56, 121-128.	0.9	122
8	Anti-Hinge Antibodies Recognize IgG Subclass– and Protease-Restricted Neoepitopes. Journal of Immunology, 2017, 198, 82-93.	0.4	25
9	Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology, 2016, 55, 939-948.	0.9	62
10	Unexpected severe incident vertebral fractures in patients with systemic lupus erythematosus: comment on the article by Zhu etÂal Lupus, 2015, 24, 222-223.	0.8	3
11	Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use. Clinical and Experimental Rheumatology, 2014, 32, 95-100.	0.4	12